安邦撤回請求批准其收購信保人壽的申請
Questions from a US regulator have prompted Anbang Insurance to drop an application for approval of its $1.57bn buyout of Fidelity & Guaranty Life, the latest regulatory hurdle faced by the Chinese company regarding a US acquisition.
美國監管機構發出的疑問，促使安邦保險(Anbang Insurance)放棄申請批准其以15.7億美元收購美國信保人壽(Fidelity & Guaranty Life)。這是中國企業在美國收購遭遇的最新一例監管障礙。
Anbang withdrew an application seeking approval for the deal from New York’s Department of Financial Services on May 27, FGL said in a filing to the US Securities and Exchange Commission.
信保人壽在提交給美國證交會(SEC)的文件中稱，5月27日安邦從紐約州金融服務管理局(Department of Financial Services)撤回了請求批准這宗交易的申請。
The company made the decision after the Department of Financial Services sought on numerous occasions “to obtain information necessary to review and process Anbang’s application”, the department said in a separate statement.
紐約州金融服務管理局在另一份聲明中表示，在安邦決定撤回申請前，該局曾多次尋求“獲得審覈和處理安邦申請所需的信息”。
Questions have long circulated around Anbang’s shareholding structure. During an eight-month period in 2014, the privately owned company’s registered capital expanded fivefold but the identity of the investors behind the expansion has never been revealed.
安邦的股權結構一直存在種種疑問。這傢俬有企業的註冊資本在2014年的8個月裏擴大了四倍，但這一擴資背後的投資者的身份卻從未被披露。
FGL said in the regulatory filing that it “expects that Anbang and its subsidiaries will refile the NY application in the near future”.
信保人壽在上述提交給監管機構的文件中表示，它“預計安邦及其附屬公司會在不遠的將來重新向紐約州提交申請”。
Anbang made a global name for itself in 2014 with the $2bn purchase of the historic Waldorf Astoria in New York. It grabbed international headlines again in March this year when its $14bn bid for Starwood Hotels & Resorts came crashing down following speculation about regulatory challenges in China.
2014年，安邦因斥資20億美元收購歷史悠久的紐約華爾道夫酒店(Waldorf Astoria Hotel)而聞名全球。今年3月，安邦因其以140億美元競購喜達屋酒店及度假村集團(Starwood Hotels & Resorts)的交易突然告吹（之前有傳聞稱安邦在中國國內遭遇監管挑戰）而再次佔據了國際媒體的頭條位置。
Given its lack of transparency, questions have been raised about Anbang’s source of funding for its global shopping spree.
鑑於其缺乏透明度，安邦在全球大肆併購所需的資金到底從何而來引發了不少疑問。
Anbang also has had issues with Chinese insurance regulators, who limit the size of bids for offshore companies as a percentage of total assets although the definition of the rule is open to question. Many Chinese entities have foreign listings to enable acquisitions without the need to seek regulatory approval at home.
安邦與中國保險業監管機構之間也存在問題，後者要求保險資金境外投資不得超過總資產的某一比例——儘管這項規定的定義值得商榷。許多中國實體在境外上市，這樣它們在海外收購時就無需尋求國內監管機構批准。
The purchase would make Anbang one of the largest insurers by market share in fixed indexed annuity products in the US.
安邦若購得信保人壽，將在美國固定指數年金產品(fixed indexed annuity products)市場上佔據較大份額。
